Cronos Group Stock And Two Cash Rich Penny Stocks Worth A Closer Look

Global markets are shifting as inflation, interest rates, bond yields and energy prices keep investors guessing. That mix can punish weaker companies that depend heavily on fresh funding. It also shines a light on a corner of the market that often gets written off too quickly. Elite penny stocks with stronger balance sheets may be better placed to keep funding their plans without relying on generous credit or speculative hype. This article focuses on our Elite Penny Stocks screener, which filters for that financial resilience, and it will walk through three highlighted stocks from the list that stand out for further research.

Cronos Group (TSX:CRON)

Overview: Cronos Group is a cannabinoid company that cultivates, produces, and sells cannabis products, including dried flower, pre-rolls, oils, vapes, edibles, and tinctures, under brands such as Spinach, Lord Jones, Lit, and Peace Naturals. It operates across Canada, Israel, and other international markets from its base in Stayner, Canada.

Operations: Cronos Group generates all of its CA$159.5 million in revenue from cannabis and cannabis derived products, with CA$95.6 million from Canada, CA$46.7 million from Israel, and CA$17.3 million from other countries.

Market Cap: CA$1.52b

Cronos Group stands out in this elite penny stocks list because it combines a sizable cash position of US$834 million and no debt with brands that already have traction in higher margin products such as vapes and edibles, including the SOURZ by Spinach Fully Blasted line that continues to expand across Canadian provinces. Analysts expect earnings and revenue to improve over time, yet the stock trades well below some fair value estimates and consensus targets. The flip side is that Cronos is still unprofitable, carries a high P/S multiple relative to peers, and depends heavily on a few key markets, all in a sector that faces ongoing regulatory uncertainty. That mix of strength and open questions is what makes the deeper story here worth your attention.

Cronos Group’s cash rich balance sheet and unprofitable status create a puzzle that many investors may be only half reading. Get the full picture with the DCF valuation analysis for Cronos Group, including one detail that could change how you frame the risk.

CEMATRIX (TSX:CEMX)

Overview: CEMATRIX manufactures and installs cellular concrete across North America, supplying lightweight, pumpable material for infrastructure, industrial, and commercial construction projects from roads and bridges to tunnels and utilities. The company focuses on on-site production that can reduce weight, improve insulation, and address complex ground conditions for engineers and contractors.

Operations: CEMATRIX generates CA$45.7 million in revenue from supplying and placing cellular concrete, with CA$11.7 million from Canada and CA$34.1 million from the United States.

Market Cap: CA$73.4 million

CEMATRIX may appeal to investors who are looking for a small construction materials company tied directly to North American infrastructure spending and the shift toward lower carbon building materials. The company focuses on cellular concrete, which can cut weight and improve thermal performance. It has a backlog that reflects a pipeline of tunnel, roadway, and utility work across Canada and the US. At the same time, revenue timing can be uneven, competition for large contracts is intense, funding relies on external borrowing, and recent results still show losses. That mix of opportunities, future contract wins in 2026, and execution risk makes CEMATRIX a stock where the details matter.

CEMATRIX’s growing backlog hints at a story that many investors may be only half seeing. Use the analysis report for CEMATRIX to see how that pipeline compares with the funding risk that still lingers.

Cannara Biotech (TSX:LOVE)

Overview: Cannara Biotech is a Canadian cannabis producer that grows, processes, and sells indoor cannabis and derivative products under the TRIBAL, nugz, and ORCHID CBD brands, while also earning income from real estate operations. The company reaches consumers mainly through wholesalers and online merchandisers from its base in Saint Laurent, Canada.

Operations: Cannara Biotech generates about CA$112.8 million from Cannabis Operations and CA$3.9 million from Real Estate Operations, with all CA$117.3 million of reported revenue coming from Canada.

Market Cap: CA$183.7 million

Cannara Biotech provides exposure to a vertically integrated cannabis producer that is already profitable, reports consistent positive adjusted EBITDA over 20 quarters, and is pushing premium formats such as infused pre rolls and vapes while expanding capacity at its Valleyfield facility. At the same time, margins have come under pressure, the Canadian retail market appears flat, and a heavy reliance on Quebec plus EU export ambitions introduces execution risk. Analysts report expectations for upside and forecast earnings growth; however, those outcomes depend on higher value export channels and better penetration in provinces such as Ontario. The interaction between capacity, pricing, and new partnerships, and how that could reshape the overall risk and reward profile, is a key consideration for investors.

Cannara Biotech’s capacity build out and premium formats story looks powerful, yet many investors may be missing how forecasts tie it all together through the analyst forecasts for Cannara Biotech that could reframe the real swing factor ahead.

The three stocks in this article are just a starting point, and the full screener has identified 11 more companies in the Elite Penny Stocks screener that carry equally compelling balance sheet strength and growth narratives. Use Simply Wall St to filter, compare, and analyze the specific catalysts and narratives that matter to you so you can identify high-conviction elite penny stock ideas with confidence.

Take Control of Your Investment Journey

If Cannara Biotech or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before They Fly Past

Fresh breakout stories often move fast once the crowd catches on. Use these curated stock lists while the data is still under the radar for now and consider your options promptly.

• Target high quality companies with robust finances before momentum builds by scanning the curated 5 high quality undervalued stocks that screens for strength while prices still look reasonable.
• Ride structural trends in automation and efficiency upgrades by checking the hand picked 34 robotics and automation stocks that highlights businesses positioned around real world robotics demand.
• Stay ahead of the next wave in digital assets infrastructure by reviewing the carefully filtered 20 cryptocurrency and blockchain stocks that focuses on listed companies tied to cryptocurrency and blockchain themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com